A Phase 3 interventional study of Etrasimod and Placebo in Ulcerative Colitis, sponsored by Arena Pharmaceuticals. Completed at 407 sites in 41 countries. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-12-21.
Sponsored by Arena Pharmaceuticals (part of Pfizer) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing etrasimod in Colitis, Ulcerative — 3 open to participants now, 5 under way, 2 of them phase 3. etrasimod · Colitis, Ulcerative.
Among the 12 studies testing etrasimod in Colitis, Ulcerative, this one is the 3rd largest by enrollment, is one of 2 that started in 2020, is one of 5 in phase 3, and was the 5th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →3 of the 12 studies testing etrasimod in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Australia, Canada and 7 more countries
Ages 2–11
Pfizer · Sites in United States, Japan, Poland and 2 more countries
Ages 12–17
Sir Run Run Shaw Hospital
Ages 18–100
By country, each count listing its studies:
etrasimod: first FDA approval 2023 (VELSIPITY), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 16 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2020.
This study's enrollment of 354 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 195 across the 12 interventional studies. Of the 7 that completed or were terminated, 7 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 12 have an industry lead sponsor. The 4 most frequent:
This study is registered under Arena Pharmaceuticals, one of the names counted as Pfizer. Under that name alone:
Arena Pharmaceuticals is the lead sponsor of 17 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
42 studies in Colitis, Ulcerative by Pfizer: 3 open now, 7 under way, 2 of them phase 3. Of 32 finished, 26 (81%) have results posted.
Among the 42 studies in Colitis, Ulcerative by Pfizer, this one is the 7th largest by enrollment of the 24 interventional ones that give a count, is one of 7 that started in 2020, is one of 9 in phase 3, and was the 22nd registered.
Pfizer’s Colitis, Ulcerative studies by the year they started, since 2005.
1 of the studies testing etrasimod in Colitis, Ulcerative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07782242Sir Run Run Shaw HospitalComaprison of Efficacy and Safety Between Etrasimod vs Mesalazine in Chinese Adults With Active UC | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing etrasimod in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 42 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy of etrasimod on clinical remission in participants with moderately to severely active ulcerative colitis (UC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Etrasimod
Drug: Placebo
Etrasimod 2 mg tablet by mouth, once daily up to 12-Week Induction Treatment Period
Also known as: APD334
Etrasimod matching placebo tablet by mouth, once daily up to 12-Week Induction Treatment Period
Percentage of Participants Achieving Clinical Remission
Clinical remission was based on the modified Mayo score (MMS). The MMS is a composite score of 3 assessments consisting of participant-reported symptoms using daily electronic (e)-diary and centrally read endoscopy: stool frequency (SF), rectal bleeding (RB) and endoscopic score (ES). Clinical remission was defined as SF sub-score = 0 (or = 1 with a greater than or equal to \[\>=\] 1-point decrease from Baseline), RB sub-score = 0, and ES less than or equal to (\<=) 1 (excluding friability). Each component sub-score ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.
Time frame: Week 12
Percentage of Participants Achieving Endoscopic Improvement
Endoscopic improvement was defined as an ES \<= 1 (excluding friability). The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease); higher score indicated more severe disease.
Time frame: Week 12
Percentage of Participants Achieving Symptomatic Remission
Symptomatic remission was defined as an SF sub-score = 0 (or = 1 with a \>= 1 point decrease from Baseline) and RB sub-score = 0. The SF sub-score ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB sub-score ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicated more severe disease.
Time frame: Week 12
Percentage of Participants With Mucosal Healing
Mucosal healing was defined as an ES \<= 1 (excluding friability) with histologic remission measured by a Geboes Index score less than \[\<\] 2.0). The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease). The Geboes score grading system, was a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicated more severe disease.
Time frame: Week 12
Percentage of Participants Achieving Clinical Response
Clinical response was based on the MMS which is a composite score of 3 assessments: SF, RB and ES. Clinical response was defined as a \>= 2-point and \>= 30 percent (%) decrease from Baseline MMS, and a \>= 1-point decrease from Baseline in RB sub-score or an absolute RB sub-score \<= 1. Each component sub-score ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.
Time frame: Week 12
Percentage of Participants Achieving Endoscopic Normalization
Endoscopic normalization was defined as an ES = 0. The ES ranged from 0 to 3 (where 0= normal/inactive disease and 3= severe disease); higher score indicated more severe disease.
Time frame: Week 12
Percentage of Participants Achieving Symptomatic Remission at Weeks 2, 4 and 8
Symptomatic remission was defined as an SF sub-score = 0 (or = 1 with a \>= 1 point decrease from Baseline) and RB sub-score = 0. The SF sub-score ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB sub-score ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicated more severe disease.
Time frame: Weeks 2, 4 and 8
Percentage of Participants Achieving Complete Symptomatic Remission
Complete symptomatic remission was defined as an SF sub-score = 0 and RB sub-score = 0. The SF sub-score ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB sub-score ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicated more severe disease.
Time frame: Weeks 2, 4, 8 and 12
Percentage of Participants Achieving Non-invasive Clinical Response
Non-invasive clinical response was defined as a \>= 30% decrease from Baseline in composite RB and SF sub-scores, and a \>= 1 point decrease from Baseline in RB sub-score or RB sub-score \<= 1. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB sub-score ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). The composite RB and SF score range was from 0 to 6, with higher scores indicating more severe disease.
Time frame: Weeks 2, 4, 8 and 12
Percentage of Participants Achieving Symptomatic Response
Symptomatic response was defined as a \>= 30% decrease from Baseline in composite RB and SF score. The SF sub-score ranged from 0 to 3 (where 0= normal number of stools and 3= at least 5 stools more than normal) and RB sub-score ranged from 0 to 3 (where 0= no blood and 3= blood alone passes). The composite RB and SF score range was from 0 to 6, with higher scores indicating more severe disease.
Time frame: Weeks 2, 4, 8 and 12
The study included a screening period (up to 28 days), a double-blind induction treatment period (12 weeks), and a 2-week and a 4-week follow-up period. The target population consisted of male or female participants aged between 16 and 80 years (inclusive), with moderately to severely active ulcerative colitis (UC).
| Milestone | Etrasimod 2 mg | Placebo |
|---|---|---|
| Started | 238 | 116 |
| Completed | 213 | 103 |
| Not completed | 25 | 13 |
| Withdrew: Protocol deviation | 1 | 1 |
| Withdrew: Physician decision | 4 | 2 |
| Withdrew: Participant decision | 0 | 1 |
| Withdrew: Lack of efficacy | 4 | 0 |
| Withdrew: Adverse event | 9 | 0 |
| Withdrew: Withdrawal by subject | 6 | 8 |
| Withdrew: Didn't meet inclusion/exclusion criteria | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
Clinical remission was based on the modified Mayo score (MMS). The MMS is a composite score of 3 assessments consisting of participant-reported symptoms using daily electronic (e)-diary and centrally read endoscopy: stool frequency (SF), rectal bleeding (RB) and endoscopic score (ES). Clinical remission was defined as SF sub-score = 0 (or = 1 with a greater than or equal to \[\>=\] 1-point decrease from Baseline), RB sub-score = 0, and ES less than or equal to (\<=) 1 (excluding friability). Each component sub-score ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Percentage of Participants Achieving Clinical Remission | 24.8 | 15.2 |
Endoscopic improvement was defined as an ES \<= 1 (excluding friability). The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease); higher score indicated more severe disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Percentage of Participants Achieving Endoscopic Improvement | 30.6 | 18.8 |
Symptomatic remission was defined as an SF sub-score = 0 (or = 1 with a \>= 1 point decrease from Baseline) and RB sub-score = 0. The SF sub-score ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB sub-score ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicated more severe disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Percentage of Participants Achieving Symptomatic Remission | 46.8 | 29.5 |
Mucosal healing was defined as an ES \<= 1 (excluding friability) with histologic remission measured by a Geboes Index score less than \[\<\] 2.0). The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease). The Geboes score grading system, was a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicated more severe disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Percentage of Participants With Mucosal Healing | 16.2 | 8.9 |
Clinical response was based on the MMS which is a composite score of 3 assessments: SF, RB and ES. Clinical response was defined as a \>= 2-point and \>= 30 percent (%) decrease from Baseline MMS, and a \>= 1-point decrease from Baseline in RB sub-score or an absolute RB sub-score \<= 1. Each component sub-score ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Percentage of Participants Achieving Clinical Response | 62.2 | 41.1 |
Endoscopic normalization was defined as an ES = 0. The ES ranged from 0 to 3 (where 0= normal/inactive disease and 3= severe disease); higher score indicated more severe disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Percentage of Participants Achieving Endoscopic Normalization | 17.1 | 8.0 |
Symptomatic remission was defined as an SF sub-score = 0 (or = 1 with a \>= 1 point decrease from Baseline) and RB sub-score = 0. The SF sub-score ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB sub-score ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicated more severe disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Week 2 | 16.2 | 10.7 |
| Week 4 | 27.5 | 16.1 |
| Week 8 | 38.7 | 24.1 |
Complete symptomatic remission was defined as an SF sub-score = 0 and RB sub-score = 0. The SF sub-score ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB sub-score ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicated more severe disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Week 2 | 4.5 | 1.8 |
| Week 4 | 11.7 | 3.6 |
| Week 8 | 14.0 | 7.1 |
| Week 12 | 18.0 | 8.9 |
Non-invasive clinical response was defined as a \>= 30% decrease from Baseline in composite RB and SF sub-scores, and a \>= 1 point decrease from Baseline in RB sub-score or RB sub-score \<= 1. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB sub-score ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). The composite RB and SF score range was from 0 to 6, with higher scores indicating more severe disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Week 2 | 39.2 | 24.1 |
| Week 4 | 55.9 | 41.1 |
| Week 8 | 68.0 | 45.5 |
| Week 12 | 67.6 | 50.0 |
Symptomatic response was defined as a \>= 30% decrease from Baseline in composite RB and SF score. The SF sub-score ranged from 0 to 3 (where 0= normal number of stools and 3= at least 5 stools more than normal) and RB sub-score ranged from 0 to 3 (where 0= no blood and 3= blood alone passes). The composite RB and SF score range was from 0 to 6, with higher scores indicating more severe disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Week 2 | 39.6 | 24.1 |
| Week 4 | 56.3 | 41.1 |
| Week 8 | 68.5 | 46.4 |
| Week 12 | 68.5 | 50.0 |
Collected over All-cause mortality, non-serious Treatment-emergent adverse events (TEAEs) and Serious adverse events (SAEs) were collected from first dose of study intervention (Day 1) up to 30 days following discontinuation of the study intervention.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Etrasimod 2 mg | 0/238 (0%) | 6/238 (2.5%) | 112/238 (47.1%) |
| Placebo | 0/116 (0%) | 2/116 (1.7%) | 54/116 (46.6%) |
| Event | Etrasimod 2 mg | Placebo |
|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 3/238 | 0/116 |
| Abdominal pain upperGastrointestinal disorders | 0/238 | 1/116 |
| AnaemiaBlood and lymphatic system disorders | 0/238 | 1/116 |
| Coronary artery diseaseCardiac disorders | 1/238 | 0/116 |
| Hepatobiliary procedural complicationInjury, poisoning and procedural complications | 1/238 | 0/116 |
| MigraineNervous system disorders | 1/238 | 0/116 |
| Event | Etrasimod 2 mg | Placebo |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 14/238 | 8/116 |
| HeadacheNervous system disorders | 11/238 | 2/116 |
| NauseaGastrointestinal disorders | 10/238 | 2/116 |
| MigraineNervous system disorders | 1/238 | 4/116 |
| Colitis ulcerativeGastrointestinal disorders | 8/238 | 1/116 |
| PyrexiaGeneral disorders | 8/238 | 3/116 |
| Abdominal painGastrointestinal disorders | 3/238 | 3/116 |
| COVID-19Infections and infestations | 3/238 | 3/116 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 3/238 | 3/116 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/238 | 3/116 |
Full Analysis Set: All randomized participants who received at least 1 dose of study intervention.
| Age, Continuous(Years) | Etrasimod 2 mg | Placebo | Total |
|---|---|---|---|
| Mean | 40.3 ± 13.49 | 40.4 ± 13.28 | 40.4 ± 13.40 |
| Sex: Female, Male(Participants) | Etrasimod 2 mg | Placebo | Total |
|---|---|---|---|
| Female | 103 | 43 | 146 |
| Male | 135 | 73 | 208 |
| Ethnicity (NIH/OMB)(Participants) | Etrasimod 2 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 10 | 9 | 19 |
| Not Hispanic or Latino | 226 | 107 | 333 |
| Unknown or Not Reported | 2 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Etrasimod 2 mg | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 6 | 1 | 7 |
| Asian | 47 | 25 | 72 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 4 |
| White | 176 | 88 | 264 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 6 | 0 | 6 |
Showing the first 100 of 407 sites across 41 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2020 to primary completion in Dec 2021, 14 months.
Results were first posted in Dec 2022, 1 year after primary completion.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 14 months is below that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Etrasimod